Search
-
-
Number of Mail Order Prescriptions Drugs by Payer
State Health Facts Indicator -
Experiences with Health Care Access, Cost, and Coverage: Findings from the 2022 KFF Women’s Health Survey
ReportThis report presents findings from the 2022 KFF Women’s Health Survey (WHS) on women’s health status, use of health care services, and costs. The WHS is a nationally representative survey of 5,145 self-identified women ages 18 to 64, conducted May 10 - June 7, 2022.
-
Most Women are in Favor of Making Birth Control Pills Available Over the Counter without a Prescription if Research Shows they are Safe and Effective
News ReleaseA new KFF survey finds that more than three-quarters (77%) of females ages 18-49 favor making birth control pills available without a doctor’s prescription if research shows they are safe and effective.
-
Number of Mail Order Prescription Drugs Per Capita
State Health Facts Indicator -
Retail Prescription Drugs Filled at Pharmacies per Capita
State Health Facts Indicator -
Number of Retail Prescription Drugs Filled at Pharmacies by Payer
State Health Facts Indicator -
Retail Sales for Prescription Drugs Filled at Pharmacies by Payer
State Health Facts Indicator -
Abortion Decision Renews Questions About Employer Access to Health Information
Policy WatchThis Policy Watch takes a look at employers ability to access abortion information when their health plan covers abortion services. With some states criminalizing entities who assist in abortions, employers and providers face legal jeopardy and existing privacy laws such as HIPAA (the Health Insurance Portability and Accountability Act) may be limited in their privacy protections.
-
Simulating the Impact of the Drug Price Negotiation Proposal in the Build Back Better Act
Issue BriefThe Build Back Better Act (BBBA) includes a range of health and other proposals supported by President Biden, including a proposal to allow the federal government to negotiate the price of some prescription drugs covered under Medicare Part B (administered by physicians) and Medicare Part D (retail outpatient drugs). This brief illustrates the potential scope of the drug price negotiation proposal in the BBBA. This analysis is designed to highlight the types of Medicare-covered drugs that could be subject to negotiation, and which of the current top-spending drugs covered by Part B and Part D could be subject to price negotiation, and in what years, if the BBBA is enacted.